Biologic treatment of psoriasis in oncologic patients

References

• Ben Abdallah H, Johansen C, Iversen L. Key signaling pathways in psoriasis: recent Insights from Antipsoriatic Therapeutics. Psoriasis Targets Ther. 2021;29(11):83–97.
   Google Scholar
• Gisondi P, Fostini AC, Fossà I, et al. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21–28.
   PubMed Web of Science ®Google Scholar
• Heitmann J, Frings VG, Geier A, et al. Non‐alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network? JDDG J. Dtsch. Dermatol. Ges. 2021;19(4): 517–528.
   Web of Science ®Google Scholar
• Carrascosa JM, Bonanad C, Dauden E, et al. Psoriasis and nonalcoholic fatty liver disease. Actas Dermosifiliogr. 2017;108(6):506–514.
   PubMed Web of Science ®Google Scholar
• Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, Incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421–429.
   PubMed Web of Science ®Google Scholar
• Rademaker M, Rubel DM, Agnew K, et al. Psoriasis and cancer. An Australian/New Zealand narrative. Australas J Dermatol. 2019;60(1):12–18.
   PubMed Web of Science ®Google Scholar
• Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: should we be paying more attention? Expert Rev Clin Immunol. 2020;16(5):479–492.
   PubMed Web of Science ®Google Scholar
• Butrón-Bris B, Daudén E, Rodríguez-Jiménez P. Psoriasis Therapy and Skin Cancer: a review. Life. 2021;11(10):1109.
   PubMedGoogle Scholar
• Yan MK, Wang C, Wolfe R, et al. Association between low-dose methotrexate exposure and melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(10):1157–1166.
   PubMed Web of Science ®Google Scholar
• Gambardella A, Licata G, Rosa AD, et al. Is apremilast a safe option in patients with history of melanoma? a case series and a review of the literature. J Clin Aesthet Dermatol. 2022;15(2):23–25.
   PubMedGoogle Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–1686.
   PubMed Web of Science ®Google Scholar
• Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69(2):400–408.
   PubMed Web of Science ®Google Scholar
• Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–1017.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1414–1420.
   PubMed Web of Science ®Google Scholar
• Papp KA, Strober B, Augustin M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J. Drugs Dermatol. JDD. 2012;11(10): 1210–1217
   PubMed Web of Science ®Google Scholar
• Geller S, Xu H, Lebwohl M, et al. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol. 2018;19(3):363–375.
   PubMed Web of Science ®Google Scholar
• Menter A, Thaçi D, Wu J, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther. 2017;7(3):365–381.
   Web of Science ®Google Scholar
• “Adalimumab - European medicines agency EMA.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
   Google Scholar
• “Etanercept - european medicines agency.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf
   Google Scholar
• “Infliximab - European medicines agency.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf
   Google Scholar
• “Certolizumab - European medicines agency.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf
   Google Scholar
• “Ustekinumab - European medicines agency.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf
   Google Scholar
• “Tildrakizumab - European medicines agency EMA.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf
   Google Scholar
• “Guselkumab - european medicines agency.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf
   Google Scholar
• “Risankizumab - European medicines agency EMA.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf
   Google Scholar
• “Ixekizumab - European medicines agency EMA.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
   Google Scholar
• “Secukinumab - European medicines agency EMA.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
   Google Scholar
• “Brodalumab - European medicines agency EMA.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf
   Google Scholar
• “Bimekizumab - European medicines agency EMA.” Aug. 15, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf
   Google Scholar
• Mastorino L, Dapavo P, Avallone G, et al. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J Dermatol Treat. 2022;33(5):2495–2502.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Carretero P, De la Cueva P, et al. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo». Actas Dermo-Sifiliográficas. 2022;113(6):583–609.
   PubMedGoogle Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2022;35(2):281–317.
   Web of Science ®Google Scholar
• De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best Pract Res Clin Rheumatol. 2018;32(6):869–886.
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Sibaud V, Fattore D, et al. Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group. J Am Acad Dermatol. 2021;84(5):1310–1320.
   PubMed Web of Science ®Google Scholar
• Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–770.
   PubMed Web of Science ®Google Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345–361.
   PubMed Web of Science ®Google Scholar
• Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor–related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268.
   PubMed Web of Science ®Google Scholar
• De Bock M, Hulstaert E, Kruse V, et al. Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review. Case Rep Dermatol. 2018;10(2):190–197.
   PubMed Web of Science ®Google Scholar
• Patel S, Patel T, Kerdel FA. The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature. Int J Dermatol. 2016;55(5):487–493.
   PubMed Web of Science ®Google Scholar
• Balato A, Lembo S, Cirillo T, et al. Anti-tumor necrosis factor-α therapy in the management of psoriasis and b-chronic lymphocytic leukemia. Case Rep Dermatol. 2011;3(1):60–63.
   PubMedGoogle Scholar
• Odorici G, Lasagni C, Bigi L, et al. A real‐life experience of psoriatic patients with history of cancer treated with biological drugs. J Eur Acad Dermatol Venereol. 2019;33(12):e453–e455.
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Arenberger P, Fridman M, et al. Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma. Dermatol Ther. 2017;30(6):e12522.
   Web of Science ®Google Scholar
• Ghazanfar MN, Karlsmark T, Danielsen PL, et al. Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis. Clin. Case Rep. 2019;7(7):1350–1351.
   PubMed Web of Science ®Google Scholar
• Jin JQ, Ahlstrom JM, Sweeney NW, et al. Clinical characteristics of 18 patients with psoriasis and multiple myeloma identified through digital health crowdsourcing. Dermatol Ther. 2020;10(4):815–827.
   Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Maurelli M, et al. IL‐17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. Dermatol Ther. 2021;34(2):e14889.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Yamauchi H, Ohtsuki M. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer. Eur. J. Dermatol. EJD. 2020;30(5):609–611.
   PubMed Web of Science ®Google Scholar
• Gambardella A. Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy. Case Rep Dermatol. 2019;11(Suppl 1):11–16.
   PubMedGoogle Scholar
• Lasagni C, Bigi L, Conti A, et al. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. J. Dermatol. Trea. 2018;29(sup2):5–8.
   PubMed Web of Science ®Google Scholar
• Wang DM, Fernandez AP, Calabrese CM, et al. Treatment of psoriasis with ustekinumab in a patient with HIV‐related Kaposi sarcoma. Clin. Exp. Dermatol. 2019;44(1):113–115.
   PubMed Web of Science ®Google Scholar
• Ju T, Hernandez L, Mohsin N, et al. Evaluation of risk in chronic cutaneous inflammatory conditions for malignant transformation. J Eur Acad Dermatol Venereol. 2022.
   Web of Science ®Google Scholar
• Gubernatorova EO, Polinova AI, Petropavlovskiy MM, et al. Dual Role of TNF and LTα in carcinogenesis as implicated by studies in mice. Cancers (Basel). 2021;13(8):1775.
   PubMed Web of Science ®Google Scholar
• Balak D, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis Targets Ther. 2017;7(7):87–94.
   PubMedGoogle Scholar
• Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31(5):e254–e257.
   PubMed Web of Science ®Google Scholar
• van Lümig PPM, Driessen RJB, Berends MAM, et al. Safety of treatment with biologics for psoriasis in daily practice: 5-year data: 5-year safety of biologics for psoriasis in daily practice. J Eur Acad Dermatol Venereol. 2012;26(3):283–291.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461–465.
   PubMed Web of Science ®Google Scholar
• Street SEA, Trapani JA, MacGregor D, et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med. 2002;196(1):129–134.
   PubMed Web of Science ®Google Scholar
• Airoldi I, Di Carlo E, Cocco C, et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood. 2005;106(12):3846–3853.
   PubMed Web of Science ®Google Scholar
• Chan IH, Jain R, Tessmer MS, et al. Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunol. 2014;7(4):842–856.
   PubMed Web of Science ®Google Scholar
• He D, Li H, Yusuf N, et al. IL-17 Mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE. 2012;7(2):e32126.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Teng MWL, Smyth MJ. A balance of interleukin-12 and −23 in cancer. Trends Immunol. 2013;34(11):548–555.
   PubMed Web of Science ®Google Scholar
• Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen X, Herjan T, et al. The role of interleukin-17 in tumor development and progression. J Exp Med. 2020;217(1):e20190297.
   PubMed Web of Science ®Google Scholar
• Chyuan I-T, Lai J-H. New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol. 2020;175:113928.
   PubMed Web of Science ®Google Scholar
• Reid PD, Cifu AS, Bass AR. Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy. JAMA. 2021;325(5):482–483.
   PubMed Web of Science ®Google Scholar
• Bertrand F, Montfort A, Marcheteau E, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):2256.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Otano I, Minute L, et al. Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. Cell Stress. 2019;3(7):236–239.
   PubMedGoogle Scholar
• Benoot T, Piccioni E, De Ridder K, et al. TNFα and immune checkpoint inhibition: friend or foe for lung cancer? Int J Mol Sci. 2021;22(16):8691.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135(8):1946–1953.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(3):1–106.
   PubMedGoogle Scholar